Agilent Technologies (NYSE:A) Price Target Raised to $165.00

Agilent Technologies (NYSE:A) had its target price lifted by Bank of America from $150.00 to $165.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the medical research company’s stock. Bank of America‘s target price suggests a potential upside of 7.68% from the company’s current price.

Several other analysts also recently weighed in on A. TD Cowen upped their price objective on Agilent Technologies from $150.00 to $162.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. UBS Group raised Agilent Technologies from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $130.00 to $170.00 in a research note on Wednesday, October 8th. Rothschild Redb raised shares of Agilent Technologies to a “strong-buy” rating in a report on Wednesday, October 8th. JPMorgan Chase & Co. raised their price target on shares of Agilent Technologies from $155.00 to $165.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Finally, Wall Street Zen raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $150.77.

Agilent Technologies Stock Performance

NYSE A opened at $153.24 on Tuesday. The firm’s 50 day simple moving average is $140.20 and its 200 day simple moving average is $125.68. The firm has a market capitalization of $43.44 billion, a price-to-earnings ratio of 35.97, a P/E/G ratio of 4.67 and a beta of 1.29. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. Agilent Technologies has a 1 year low of $96.43 and a 1 year high of $153.84.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Monday, November 24th. The medical research company reported $1.59 EPS for the quarter, beating the consensus estimate of $1.58 by $0.01. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business had revenue of $1.86 billion during the quarter, compared to the consensus estimate of $1.83 billion. During the same period in the previous year, the business earned $1.46 earnings per share. The company’s revenue was up 9.4% on a year-over-year basis. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS. FY 2026 guidance at 5.860-6.000 EPS. As a group, research analysts expect that Agilent Technologies will post 5.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 911 shares of the stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $143.24, for a total transaction of $130,491.64. Following the completion of the sale, the chief executive officer owned 32,058 shares of the company’s stock, valued at approximately $4,591,987.92. This represents a 2.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.26% of the stock is owned by insiders.

Institutional Investors Weigh In On Agilent Technologies

A number of institutional investors have recently modified their holdings of A. CIBC Bancorp USA Inc. acquired a new stake in shares of Agilent Technologies during the third quarter worth $5,030,000. Center For Asset Management LLC acquired a new stake in Agilent Technologies in the 3rd quarter valued at $234,000. Captrust Financial Advisors grew its position in Agilent Technologies by 2.4% in the 3rd quarter. Captrust Financial Advisors now owns 43,179 shares of the medical research company’s stock valued at $5,542,000 after purchasing an additional 1,021 shares during the period. Coldstream Capital Management Inc. increased its stake in Agilent Technologies by 16.8% during the 3rd quarter. Coldstream Capital Management Inc. now owns 5,640 shares of the medical research company’s stock valued at $724,000 after purchasing an additional 813 shares in the last quarter. Finally, Danske Bank A S acquired a new position in Agilent Technologies during the third quarter worth $51,528,000. 87.41% of the stock is owned by institutional investors.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.